000286091 001__ 286091
000286091 005__ 20260413130401.0
000286091 0247_ $$2doi$$a10.1016/j.tjpad.2026.100556
000286091 0247_ $$2pmid$$apmid:41935406
000286091 0247_ $$2ISSN$$a2274-5807
000286091 0247_ $$2ISSN$$a2426-0266
000286091 037__ $$aDZNE-2026-00387
000286091 041__ $$aEnglish
000286091 082__ $$a610
000286091 1001_ $$aSannemann, Lena$$b0
000286091 245__ $$aDementia risk factor assessment in a local Alzheimer's prevention population: a German cross-sectional, observational study.
000286091 260__ $$a[Paris]$$bElsevier Masson SAS$$c2026
000286091 3367_ $$2DRIVER$$aarticle
000286091 3367_ $$2DataCite$$aOutput Types/Journal article
000286091 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1776077933_32198
000286091 3367_ $$2BibTeX$$aARTICLE
000286091 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286091 3367_ $$00$$2EndNote$$aJournal Article
000286091 520__ $$aThe risk for dementia is to a significant extent driven by potentially modifiable factors. Prevention strategies are increasingly aiming at individually tailored risk reduction approaches, particularly in light of emerging Brain Health Services for dementia prevention (dBHS).The cross-sectional observational study 'Individual Risk Profiling for Alzheimer's and Dementia Prevention' (INSPIRATION) assessed the individual risk factors of 162 participants of the local Cologne Alzheimer Prevention Registry and provided individual feedback on risk profiles during a single visit. We analysed the frequency and patterns of risk factors and explored their association with cognition and Alzheimer's disease (AD) plasma biomarkers.The most common risk factors in this population were obesity, non-adherence to a Mediterranean diet, low subjective sleep quality, subjective experience of stress, and hearing impairment. A principal component analysis (PCA) revealed six principal components (PC), which we labeled as (1) psychosocial factors, (2) blood pressure, (3) physical condition, (4) hearing impairment, (5) lifestyle, and (6) substance use. We found isolated associations between PCs, cognition, and AD plasma biomarkers.These findings provide initial insights into which risk factors may be most relevant and actionable for highly-educated and prevention-motivated populations likely to seek dBHS. Interventions addressing the domains of psychosocial factors, physical condition, and lifestyle may be particularly relevant to consider for a personally tailored risk reduction approach in comparable populations.The study was funded by research funds of the Medical Faculty and the University Hospital Cologne, University of Cologne and the non-profit association Kölner Verein für seelische Gesundheit e.V.
000286091 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000286091 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000286091 650_7 $$2Other$$aAlzheimer’s disease
000286091 650_7 $$2Other$$aDementia
000286091 650_7 $$2Other$$aModifiable risk factors
000286091 650_7 $$2Other$$aPrevention
000286091 650_7 $$2Other$$aRisk assessment
000286091 650_7 $$2Other$$aRisk communication
000286091 7001_ $$0P:(DE-2719)9003021$$aGerards, Michelle$$b1$$udzne
000286091 7001_ $$aBohr, Lara$$b2
000286091 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b3$$udzne
000286091 7001_ $$0P:(DE-2719)9002022$$aEscher, Claus$$b4$$udzne
000286091 7001_ $$aKalthegener, Franziska$$b5
000286091 7001_ $$aMüller, Theresa$$b6
000286091 7001_ $$0P:(DE-2719)2812825$$aRamírez, Alfredo$$b7$$udzne
000286091 7001_ $$aZeyen, Philip$$b8
000286091 7001_ $$0P:(DE-2719)2000032$$aJessen, Frank$$b9$$udzne
000286091 7001_ $$aRostamzadeh, Ayda$$b10
000286091 773__ $$0PERI:(DE-600)2782183-3$$a10.1016/j.tjpad.2026.100556$$gVol. 13, no. 6, p. 100556 -$$n6$$p100556$$tThe journal of prevention of Alzheimer's disease$$v13$$x2274-5807$$y2026
000286091 8564_ $$uhttps://pub.dzne.de/record/286091/files/DZNE-2026-00387.pdf$$yRestricted
000286091 8564_ $$uhttps://pub.dzne.de/record/286091/files/DZNE-2026-00387.pdf?subformat=pdfa$$xpdfa$$yRestricted
000286091 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003021$$aExternal Institute$$b1$$kExtern
000286091 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000286091 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002022$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000286091 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812825$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000286091 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000032$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000286091 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000286091 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-11$$wger
000286091 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-11$$wger
000286091 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJPAD-J PREV ALZHEIM : 2022$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2025-05-28T09:11:42Z
000286091 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2025-05-28T09:11:42Z
000286091 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2025-05-28T09:11:42Z
000286091 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJPAD-J PREV ALZHEIM : 2022$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-11-11
000286091 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-11-11
000286091 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x0
000286091 9201_ $$0I:(DE-2719)1011102$$kAG Jessen$$lClinical Alzheimer’s Disease Research$$x1
000286091 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x2
000286091 9201_ $$0I:(DE-2719)1011101$$kPatient Studies (Bonn)$$lPatient Studies (Bonn)$$x3
000286091 980__ $$ajournal
000286091 980__ $$aEDITORS
000286091 980__ $$aVDBINPRINT
000286091 980__ $$aI:(DE-2719)1011303
000286091 980__ $$aI:(DE-2719)1011102
000286091 980__ $$aI:(DE-2719)1011001
000286091 980__ $$aI:(DE-2719)1011101
000286091 980__ $$aUNRESTRICTED